Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 23.04B |
| Revenue (ttm) | 8.58B |
| Net Income (ttm) | 1.37B |
| Shares Out | n/a |
| EPS (ttm) | 9.35 |
| PE Ratio | 16.80 |
| Forward PE | 13.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15 |
| Average Volume | 875 |
| Open | 157.90 |
| Previous Close | 157.35 |
| Day's Range | 157.00 - 157.90 |
| 52-Week Range | 99.00 - 160.90 |
| Beta | 0.15 |
| RSI | 83.75 |
| Earnings Date | Feb 12, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved, ...
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
Biogen Inc. (NASDAQ: BIIB) stock traded higher after Novo Nordisk A/S (NYSE: NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-st...
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
CAMBRIDGE, Mass. and TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Dayra Therapeutics today announced a research collaboration to discover and develop oral macrocyclic pept...
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership
TORONTO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Versant Ventures today announced the launch of Dayra Therapeutics, a startup focused on developing oral macrocyclic peptides for a range of serious disease...
Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.
The drugmaker announces that Ozempic didn't slow the progression of Alzheimer's in two clinical trials.
AI Stocks Are Taking a Beating. What to Buy Instead.
Healthcare stocks may have more momentum. But the AI trade isn't dead yet.
Piper Sandler Reiterates Neutral Rating on Biogen (BIIB), Raises Price Target | BIIB Stock News
Piper Sandler Reiterates Neutral Rating on Biogen (BIIB), Raises Price Target | BIIB Stock News
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
New lecanemab findings highlight the safety and potential benefits of subcutaneous administration for initiation dosing, the potential for additional long-term clinical benefits with continued treatme...
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference
CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, t...
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.
Biogen Options Trading: A Deep Dive into Market Sentiment
High-rolling investors have positioned themselves bullish on Biogen (NASDAQ: BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's t...
Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Study
Biogen (BIIB) and Stoke Release Results from Dravet Syndrome Study
Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study
Biogen (BIIB) Reveals Key Findings from Dravet Syndrome Study
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today an...
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative ...
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
Biogen (BIIB) Advances High Dose Spinal Muscular Atrophy Treatment in Europe
Biogen (BIIB) Advances High Dose Spinal Muscular Atrophy Treatment in Europe
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted ...
STATE STREET CORP Reduces Stake in Biogen Inc: A Detailed Analysis
STATE STREET CORP Reduces Stake in Biogen Inc: A Detailed Analysis
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CN...
Biogen (BIIB) Gains UK Approval for LEQEMBI Maintenance Dosing
Biogen (BIIB) Gains UK Approval for LEQEMBI Maintenance Dosing
Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
What the Options Market Tells Us About Biogen
Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ: BIIB). And retail traders should know. We noticed this today when the trades showed up on publicly available opti...